229 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (55)
- Allergy, Asthma, & Immunology (1)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (5)
- Bone & Muscle (1)
- Cancer (8)
- COVID-19 (Coronavirus) (2)
- Diabetes (1)
- Gastrointestinal and Digestive Diseases (1)
- Hair and Skin Disorders (3)
- Healthy Volunteers (11)
- Heart Disease (3)
- (-) Infectious Disease (2)
- Kidney Disease (1)
- Lung Disease (5)
- (-) Neurological Disorders (2)
- Obstetrics & Gynecology (2)
- Pediatrics (2)
- Psychiatric Disorders (1)
- Rehabilitation (1)
- Transplant (1)
- Vascular Conditions (1)
Displaying 1 - 4 of 4
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Currently Recruiting
We are conducting a research study to see if hormone therapy (HT) helps reduce hot flashes and night sweats in women living with HIV in the late menopausal transition (similar to what is known as perimenopause) or early post-menopause (the time after the final menstrual period or after removal of both ovaries). If you were assigned female sex at birth, are…
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Currently Recruiting
Are you suffering from persistent symptoms that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new research study aims to test a new form of treatment for people with persistent symptoms despite antibiotic treatment for Lyme disease. This treatment involves stimulating a nerve on the surface of your ear. This is called…
Condition: Neurological Disorders
Investigator: Cheryl Waters, MD
Status: Closed
The purpose of this study is to test the effectiveness of investigational drug APL-130277 for patients with Parkinson's disease. APL-130277 is an investigational drug, which means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). The active ingredient in APL-130277 is apomorphine, a medication…
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.